Intensity Therapeutics, Inc. (INTS) Stock Price & Analysis
Intensity Therapeutics, Inc. (INTS) rose 2.50% to USD 4.1 as of September 8, 2026 at 12:02 UTC, according to Nexqual real-time market data.
INTS last closed at USD 4.1; the session ranged USD 3.99–4.11 on volume of 4,494 shares. Market capitalization is —, with a 52-week range of USD 3.51–43.5 (NCM). Source: Nexqual, September 8, 2026 at 12:02 UTC.
Key Statistics (as of September 8, 2026 at 12:02 UTC)
| Price | USD 4.1 |
|---|---|
| Change | ▲ 2.50% (up) |
| Previous Close | USD 4.1 |
| Open | USD 4.1 |
| Day Range | USD 3.99 – 4.11 |
| 52-Week Range | USD 3.51 – 43.5 |
| Volume | 4,494 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (INTS)
Nexqual's technical model rates INTS "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.27 (neutral) |
| vs SMA50 | Below (USD 4.4) |
| MACD | -0.07 (negative) |
From Intensity Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- If we successfully execute the agreed-upon plan, we expect that the CMC portion of a New Drug Application ("NDA") should be acceptable to the FDA for product approval and registration (subject to final NDA review).
- Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules.
- Our Proprietary Drug Discovery platform, DfuseRx SM Since our inception, we have conducted research using our discovery platform.
- Our technology platform allows us to identify novel product formulations and test the products' activity in animal or test tube models of cancer.
Partnerships
- In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.
- In 2020, as part of our IT-01 Study, we entered into an agreement with BMS to evaluate the safety and efficacy of INT230-6 with Yervoy ® (ipilimumab), BMS's CTLA-4 immune checkpoint inhibitor, in patients with breast (17%), liver (5%), and advanced sarcoma cancer (78%).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MSAI | MultiSensor AI Holdings, Inc. | USD 4.87 | ▼ 3.56% |
| FEMY | Femasys Inc. | USD 2.98 | ▼ 3.87% |
| AIRE | reAlpha Tech Corp. | USD 1.5 | ▼ 1.32% |
| IXHL | Incannex Healthcare Inc. | USD 3.25 | ▼ 0.76% |
| PCSA | Processa Pharmaceuticals, Inc. | USD 2.06 | ▼ 1.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:02 UTC. This page is informational and not investment advice.